Navigation Links
Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc.
Date:5/16/2010

TOKYO and MELVILLE, N.Y. May 16 /PRNewswire-FirstCall/ -- Astellas Pharma Inc. (TSE: 4503), a global pharmaceutical company, and OSI Pharmaceuticals, Inc. (Nasdaq: OSIP), a biotechnology company primarily focused on the discovery, development and commercialization of molecular targeted therapies addressing medical needs in oncology, diabetes and obesity, today announced that they have entered into a definitive merger agreement under which Astellas will acquire OSI.

Under the terms of the merger agreement, Astellas will increase its offer price to $57.50 per share, which represents a premium of 55% to the closing price for OSI's shares of $37.02 on February 26, 2010, the last trading day before the announcement by Astellas of its tender offer. The boards of directors of both companies have unanimously approved the combination. The all-cash transaction is valued at $4.0 billion on a fully diluted basis.

The combined company creates a world-class oncology platform supporting Astellas' stated growth strategy of becoming a Global Category Leader in Oncology, a high-priority therapeutic area for Astellas. OSI commercializes Tarceva® (erlotinib), a leading cancer medication. OSI's total annual revenues for 2009, as reported in its Form 10-K for the year ended December 31, 2009, were $428 million and operating income was $153 million.

Masafumi Nogimori, President and Chief Executive Officer of Astellas, said, "The merger with OSI prov
'/>"/>

SOURCE Astellas Pharma US, Inc.; OSI Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC
2. Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program
3. Astellas and Boehringer Ingelheim Reach Settlement Agreement with Ranbaxy on Flomax Patent Case
4. CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM) (regadenoson) Injection
5. Astellas Launches Lexiscan(TM) (Regadenoson) Injection for Use as a Pharmacologic Stress Agent in Radionuclide Myocardial Perfusion Imaging (MPI)
6. FDA Approves Astellas Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
7. CV Therapeutics Statement on Unsolicited Proposal From Astellas
8. CV Therapeutics Board of Directors Rejects Astellas Unsolicited Proposal
9. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
10. CV Therapeutics Board of Directors Rejects Astellas Tender Offer
11. Astellas Receives FDA Approval for Use of Prograf(R) (Tacrolimus) in Conjunction With Mycophenolate Mofetil (MMF) in Kidney Transplant Recipients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... August 28, 2015 , ... Since the initial launch of FireflySci Inc. (FFS) in early ... excellent customer service. Images such as the Fonz in a lab coat and Large ... to the humdrum spectroscopy field. , FireflySci is proud to be the only ...
(Date:8/27/2015)... -- The National Necrotizing Fasciitis Foundation (NNFF) ... doctors at Vanderbilt University Hospital in Nashville, ... Dr. John Crew , director of the ... in Daly City, CA. ... by Dr. Crew, that had previously saved the lives ...
(Date:8/27/2015)... ... August 27, 2015 , ... Inc. Magazine released its annual ... Solutions as number 1,361 in growth for the three years through 2014. Being named ... fastest-growing privately held organizations in the country. , “We are thrilled to make ...
(Date:8/26/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended June 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Oral Amp B program, rapidly advancing towards the ... Rae , President & CEO of iCo Therapeutics. "We ...
Breaking Biology Technology:Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3
... NuVasive, Inc. (Nasdaq: NUVA ), a medical device ... for the spine, announced today financial results for the quarter ... of $94.9 million, a 41.8% increase over the $66.9 million ... the $88.5 million for the second quarter 2009. ...
... Reserve University Biomedical Engineering Department has set trends for ... aged, the critically ill and traumatically injured. The department ... celebrates its 40th anniversary, Thursday, Oct. 22. , Case ... nation to offer graduate and undergraduate biomedical engineering programs ...
... Calif., Oct. 20 Transdel Pharmaceuticals, Inc. (OTC Bulletin ... topically administered products using its proprietary transdermal delivery platform, ... Executive Officer of Transdel, will present a company ... present at the 4th annual BIOCOM Investor Conference in ...
Cached Biology Technology:NuVasive Reports Third Quarter 2009 Financial Results 2NuVasive Reports Third Quarter 2009 Financial Results 3NuVasive Reports Third Quarter 2009 Financial Results 4NuVasive Reports Third Quarter 2009 Financial Results 5NuVasive Reports Third Quarter 2009 Financial Results 6NuVasive Reports Third Quarter 2009 Financial Results 7NuVasive Reports Third Quarter 2009 Financial Results 8NuVasive Reports Third Quarter 2009 Financial Results 9NuVasive Reports Third Quarter 2009 Financial Results 10NuVasive Reports Third Quarter 2009 Financial Results 11NuVasive Reports Third Quarter 2009 Financial Results 1240 Years on the Leading Edge: Case Western Reserve University's Biomedical Engineering Department Commemorates Achievement, Looks to Future 2Transdel Pharmaceuticals to Present at Two Investor Conferences 2Transdel Pharmaceuticals to Present at Two Investor Conferences 3
(Date:8/20/2015)... , Aug. 20, 2015   Sensory, Inc ... improving the user experience and security of consumer ... today announced that its TrulySecure™ is ... software to be FIDO Certified™. The ... compliance with the FIDO UAF (Universal Authentication Framework) ...
(Date:8/18/2015)... Aug. 17, 2015 Research and Markets ... the "Global Biometric Authentication & Identification Market: ... & Forecast, 2015-2020" report to their offering. ... identification systems market is expected to grow at ... 2020 and generate over $25 billion (approximately) by ...
(Date:8/12/2015)... NEW YORK , Aug. 12, 2015 /PRNewswire/ ... how hackers can attack Android phones to steal ... identifies the increasing availability of fingerprint scanners on ... of utmost concern. To secure biometrics on mobile ... platform to augment these convenient authentication systems with ...
Breaking Biology News(10 mins):TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3
... 2012 /PRNewswire-iReach/ -- Global Information Inc. is excited ... for Boston, MA in the Spring of 2012. ... April 30 – May 4, 2012 : Cambridge Healthtech Institute ... in Boston, MA. This comprehensive event encompasses 12 tracks, ...
... 14, 2012) A research team has identified epigenetic ... gene expression, within reprogrammed skin cells. These signatures can ... skin cells or induced pluripotent stem cells (iPSCs), cells ... the expression of the protein is controlled brings us ...
... Gutenberg University Mainz (JGU) in Germany have developed a ... the dynamics of proteins is necessary in order to ... molecular level. To date, this information has been obtained ... unfortunately this changes the proteins under investigation and thus ...
Cached Biology News:Annual Drug Discovery Conferences Being Held in Boston MA, Spring 2012 2Annual Drug Discovery Conferences Being Held in Boston MA, Spring 2012 3Epigenetic signatures direct the repair potential of reprogrammed cells 2Gold nanoantennas detect proteins 2
Mouse anti-hepatitis delta virus Class: Antibody Product Group: Bacterial and Viral Antigen...
TTC4 Antibody...
Mouse monoclonal [LH8] to Cytokeratin 5 + 14 ( Abpromise for all tested applications). entrezGeneID: 3852 SwissProtID: P02533...
...
Biology Products: